Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New imaging technique identifies glioblastoma patients who would benefit from immunotherapy

2.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

3.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

4.

Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

5.

Targeted radiation therapy shows near-complete response in rare sarcoma patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot